But TIGIT has not lived up to the hype, at least not yet. The most recent setback occurred just last week, when Roche reported the failure of its anti-TIGIT antibody in a Phase 3 study involving ...

The study also included a pre-clinical component where a mouse model of human NHL was used to assess the potential impact of TIGIT blockade. The researchers found that blocking TIGIT, in combination ...

When added to GSK’s drug Jemperli, the immunotherapy, known as belrestotug and aimed at a cellular target called TIGIT, didn’t meet preset criteria for progression-free survival compared to ...

While TIGIT was once hyped as the next great immunotherapy target, a number of failed trials has cooled that sentiment, and some drugmakers have pared their TIGIT programs.

Like PD-L1, TIGIT is an immune checkpoint that acts as a “brake” to stop T cells from attacking tumors. They work in parallel, so, if you block one, the other will still work, Le said.

Merck & Co.'s TIGIT therapy tacked on to Keytruda did not improve progression-free survival in a phase 2 lung cancer trial, marking the latest failure for the class. The company reported open ...

ITOS is tantalizing, not sure if TIGIT class lives up to promise, but I believe they have the best shot on goal bc they have the only TIGIT to show mono-therapy activity, and based on the success ...

Roche's (RHHBY) lung cancer drug tiragolumab fails in a clinical trial, hurting the shares of its rival anti-TIGIT developers, Compugen and Arcus. Read more here.

ARC-7 is a Phase 2, multicenter, three-arm, randomized, open-label study evaluating the combinations of Fc-silent anti-TIGIT monoclonal antibody domvanalimab plus anti-PD1 monoclonal antibody ...

Arcus is developing a second anti-TIGIT candidate, AB308, an Fc-enabled investigational monoclonal antibody in clinical development, with a potential focus on hematological malignancies.

TIGIT expression can cause T cell exhaustion and NK cell immunosuppression. Thus, it is thought that targeting TIGIT could help reactivate T and NK cells while also suppressing tumor expansion.

FACS Figure 6. FACS assay shows that Human TIGIT, His Tag (Cat. No. TIT-H52H3) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT used is 0.3 μg/mL. Table 2. Product list.